Bill Text: CA SB1442 | 2023-2024 | Regular Session | Amended
Bill Title: Point-of-care tests for fentanyl.
Spectrum: Moderate Partisan Bill (Democrat 4-1)
Status: (Engrossed) 2024-08-15 - August 15 hearing: Held in committee and under submission. [SB1442 Detail]
Download: California-2023-SB1442-Amended.html
|
Amended
IN
Assembly
June 13, 2024 |
|
Amended
IN
Senate
May 16, 2024 |
|
Amended
IN
Senate
March 18, 2024 |
CALIFORNIA LEGISLATURE—
2023–2024 REGULAR SESSION
Senate Bill
No. 1442
| Introduced by Senators Ochoa Bogh and Skinner |
February 16, 2024 |
An act to add Section 127697.1 to the Health and Safety Code, relating to public health.
LEGISLATIVE COUNSEL'S DIGEST
SB 1442, as amended, Ochoa Bogh.
Point-of-care tests for fentanyl.
Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified.
This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law.
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NOBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 127697.1 is added to the Health and Safety Code, to read:127697.1.
(a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law.(b) For purposes of this section, “point-of-care test for fentanyl” means a point-of-care test for use by a provider
to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine.
